Oxford Biomedica PLC OXB to present at JMP Securities
June 23 2015 - 7:00AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
23 June 2015
Oxford BioMedica to present at JMP Securities Life Sciences
Conference 2015 in New York and to attend ROTH Healthcare Day in
London
Oxford, UK - 23 June 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, announces that Chief Executive Officer John Dawson
will present today at the 2015 JMP Securities Life Sciences
Conference in New York at 1600-1630 ET (2100-2130 BST).
Tim Watts, Chief Financial Officer of Oxford BioMedica will also
be in attendance at the 2nd Annual ROTH Healthcare Day, held in
London on the 24th June 2015.
A live-streaming webcast of the JMP conferencepresentation will
be available at http://wsw.com/webcast/jmp27/oxb.l. An archived
copy of the presentation will also be made available on the Oxford
BioMedica website following the event.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy Group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that
are inadequately treated today, including ocular and central
nervous system disorders. OXB Solutions, the Group's
industry-leading manufacturing and development business, provides
services to collaborators and partners working in gene and cell
therapy, including Novartis and Immune Design Corp. In addition,
the Group has licenced products and IP to Sanofi, Pfizer,
GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent
BioSolutions and ImaginAb. Further information is available at
www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKNDQKBKDCAB
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024